messag provid updat model reflect chang
account standard come effect adjust
ep estim decreas respect
opdivo estim move
believ opdivo key revenu driver continu
strong growth follow readout first-lin lung cancer interim
analysi expect earli follow final analysi
interim analysi earli
manag recent reiter expect interim analysi lung cancer trial
take place earli final analysi come
import trial readout horizon
offer multipl option take share nsclc set reiter buy rate
continu believ nonsignific result astrazeneca azn mystic
trial direct read-through believ crucial molecular
differ yervoy tremelimumab well opdivo imfinzi
note morn provid outlook in-depth discuss
well top ten io trial outcom mean
treatment paradigm market share
updat estim base chang account standard
come effect chang includ amend guidanc revenu
recognit refer use modifi retrospect method
cumul effect chang recogn retain earn result new
guidanc cumul effect adjust revenu expect lower
comparison revenu would report prior account
chang chang report revenu result royalti paid compani
sanofi sni longer effect
chang account pension benefit cost also come effect
retrospect basi amend guidanc requir net period benefit compon
defin benefit pension post-retir plan servic cost
record outsid incom expect oper expens increas
million follow correspond off-set incom incom
expect lower compar would report
previou standard due termin payment book retain earn
sustiva patent expir end thu expect sustiva
revenu declin precipit howev believ sustiva revenu ex-u
remain strong expir importantli receiv cent dollar
sold atripla agreement reduc percent
expect dissolv three year compani hcv
franchis experienc pressur china two import factor consid
cash pay china exist shadow market china daklinza
sale daklinza shadow market indian gener cost roughli
cours treatment yet price thu effect sale
daklinza chines market
adjust ep estim decreas
respect ep estim repres declin cent
previou estim primarili result account chang went effect
first half lower revenu estim opdivo
opdivo estim move though
page analyst certif import disclosur
lower estim believ opdivo key revenu driver
continu strong growth domest intern belief
opdivo growth strong base view readout first-lin lung
valuat risk
valuat maintain price target base dcf analysi use
unchang wacc lt growth rate import trial
readout horizon offer multipl option take share nsclc
set maintain buy rate
risk risk rate estim price target includ larger anticip
impact competit pressur hep space impact loe product
reyataz sustiva neg readout setback
clinic pipelin increas pressur price brand product price
debat continu competit pressur io space
page analyst certif import disclosur
million except per-shar figur
revenu geographi
good sold
cog royalti share product
equiti incom affili
convert debt interest expense/dividend attribut unvest share
compani document guggenheim secur llc estim
page analyst certif import disclosur
